Sakar Healthcare Limited's oncology unit, located in Bavla, Ahmedabad, has been approved by the European Medical Agency (EMA) for the manufacturing of Imatinib Accord 100 mg and 400 mg film-coated tablets. This approval allows Sakar to supply these products to Accord Healthcare's European market. This achievement is a result of the collaborative efforts between Accord, Intas, and Sakar. The inclusion of Imatinib marks the first of nine Accord oncology products for which Sakar will be the manufacturing source. This development is expected to positively impact Sakar's top-line sales in the upcoming fiscal year due to improved capacity utilization. With this approval, Sakar is now poised to supply a dozen approved products to overseas markets.